AU2007346591A1 - Treatment of ADHD - Google Patents
Treatment of ADHD Download PDFInfo
- Publication number
- AU2007346591A1 AU2007346591A1 AU2007346591A AU2007346591A AU2007346591A1 AU 2007346591 A1 AU2007346591 A1 AU 2007346591A1 AU 2007346591 A AU2007346591 A AU 2007346591A AU 2007346591 A AU2007346591 A AU 2007346591A AU 2007346591 A1 AU2007346591 A1 AU 2007346591A1
- Authority
- AU
- Australia
- Prior art keywords
- individual
- mood
- mood stabiliser
- epileptic
- stabiliser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title claims description 60
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title claims description 51
- 238000011282 treatment Methods 0.000 title description 30
- 238000000034 method Methods 0.000 claims description 87
- 229940127237 mood stabilizer Drugs 0.000 claims description 74
- 239000004050 mood stabilizer Substances 0.000 claims description 65
- 239000001961 anticonvulsive agent Substances 0.000 claims description 52
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 50
- 230000003556 anti-epileptic effect Effects 0.000 claims description 49
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 40
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical group [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 40
- 239000003368 psychostimulant agent Substances 0.000 claims description 39
- 229940084026 sodium valproate Drugs 0.000 claims description 31
- 230000004434 saccadic eye movement Effects 0.000 claims description 23
- 230000036651 mood Effects 0.000 claims description 21
- 230000006641 stabilisation Effects 0.000 claims description 19
- 208000020925 Bipolar disease Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000003920 cognitive function Effects 0.000 claims description 13
- 206010053694 Saccadic eye movement Diseases 0.000 claims description 11
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 10
- 206010015037 epilepsy Diseases 0.000 claims description 10
- 238000012163 sequencing technique Methods 0.000 claims description 10
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 9
- 230000002490 cerebral effect Effects 0.000 claims description 9
- 229960004394 topiramate Drugs 0.000 claims description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 7
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 7
- 229960000623 carbamazepine Drugs 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 229960001344 methylphenidate Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 5
- 229960002870 gabapentin Drugs 0.000 claims description 4
- 229960001848 lamotrigine Drugs 0.000 claims description 4
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960001816 oxcarbazepine Drugs 0.000 claims description 4
- 229960000761 pemoline Drugs 0.000 claims description 4
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 4
- 229960002393 primidone Drugs 0.000 claims description 4
- 229960001918 tiagabine Drugs 0.000 claims description 4
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 4
- -1 amphetamines Chemical compound 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 206010013932 dyslexia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 230000006872 improvement Effects 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 230000006870 function Effects 0.000 description 18
- 230000001755 vocal effect Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 12
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 11
- 206010026749 Mania Diseases 0.000 description 9
- 230000001149 cognitive effect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 229940102566 valproate Drugs 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 210000001638 cerebellum Anatomy 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000003340 mental effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000003936 working memory Effects 0.000 description 6
- 208000020358 Learning disease Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000001037 epileptic effect Effects 0.000 description 5
- 230000004424 eye movement Effects 0.000 description 5
- 201000003723 learning disability Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 239000000021 stimulant Substances 0.000 description 5
- 238000011287 therapeutic dose Methods 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000010365 information processing Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008449 language Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002269 analeptic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000010326 executive functioning Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000011977 language disease Diseases 0.000 description 3
- 230000003565 oculomotor Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000012239 Developmental disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 241000287433 Turdus Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 2
- 229960002767 ethosuximide Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 229960001930 valpromide Drugs 0.000 description 2
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 description 1
- RGZUPIWJTSGERU-UHFFFAOYSA-N 2-propylpentanoic acid;sodium Chemical compound [Na].CCCC(C(O)=O)CCC RGZUPIWJTSGERU-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical class CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 229940112502 concerta Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940089052 depakene Drugs 0.000 description 1
- 229940075925 depakote Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940053650 focalin Drugs 0.000 description 1
- 239000003445 gaba agent Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000001475 oxazolidinediones Chemical class 0.000 description 1
- 229960003274 paramethadione Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960004227 phensuximide Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000009023 proprioceptive sensation Effects 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 230000001711 saccadic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940035305 topamax Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- DJEFRLDEQKSNLM-UHFFFAOYSA-N valproate pivoxil Chemical compound CCCC(CCC)C(=O)OCOC(=O)C(C)(C)C DJEFRLDEQKSNLM-UHFFFAOYSA-N 0.000 description 1
- 229950007349 valproate pivoxil Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90004307P | 2007-02-07 | 2007-02-07 | |
| US60/900,043 | 2007-02-07 | ||
| PCT/AU2007/000421 WO2008095221A1 (en) | 2007-02-07 | 2007-03-30 | Treatment of adhd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007346591A1 true AU2007346591A1 (en) | 2008-08-14 |
Family
ID=39681166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007346591A Abandoned AU2007346591A1 (en) | 2007-02-07 | 2007-03-30 | Treatment of ADHD |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8957099B2 (https=) |
| EP (2) | EP2129369B1 (https=) |
| JP (2) | JP5586962B2 (https=) |
| AU (1) | AU2007346591A1 (https=) |
| ES (1) | ES2426764T3 (https=) |
| WO (2) | WO2008095221A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
| DK3260118T3 (da) | 2008-10-16 | 2021-04-19 | Univ Johns Hopkins | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| EA202092673A3 (ru) * | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| JP2013523757A (ja) * | 2010-03-31 | 2013-06-17 | スパーナス ファーマシューティカルズ インコーポレイテッド | マジンドールの製剤 |
| KR20120021694A (ko) * | 2010-08-13 | 2012-03-09 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ?타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| PL220308B1 (pl) | 2011-06-03 | 2015-10-30 | Kobel Buys Krystyna | Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego |
| CA2840812A1 (en) * | 2011-07-05 | 2013-01-10 | Robert Don HUNT | Systems and methods for clinical evaluation of psychiatric disorders |
| GB201111712D0 (en) * | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| WO2013039271A1 (ko) * | 2011-09-16 | 2013-03-21 | 한국과학기술원 | 뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물 |
| WO2013183985A1 (en) * | 2012-06-05 | 2013-12-12 | Erasmus University Medical Center Rotterdam | Method of treating cognitive impairment and compounds for use therein |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR101625575B1 (ko) * | 2013-03-21 | 2016-06-13 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| EP2886116A1 (en) * | 2013-12-18 | 2015-06-24 | Biocodex | Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity |
| AU2014371437B2 (en) * | 2013-12-25 | 2020-01-30 | Fujimoto Co., Ltd. | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder |
| CN105380935B (zh) * | 2014-09-03 | 2018-04-03 | 长春海悦药业股份有限公司 | 一种丙戊酸钠药物组合物 |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| IL256912B2 (en) | 2015-07-17 | 2024-01-01 | Ovid Therapeutics Inc | Methods of treating developmental disorders with gaboxadol |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| KR20190013737A (ko) * | 2016-05-26 | 2019-02-11 | 오비드 테라퓨틱스 인크. | 피프라드롤을 이용한 행동 증후군들의 치료 방법들 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| GB202101462D0 (en) * | 2021-02-03 | 2021-03-17 | Sanchez Hector Mario | Combination therapy for treating executive function disorders |
| CA3209813A1 (en) | 2021-07-14 | 2023-01-19 | Mydecine Innovations Group Inc. | Novel short-acting psychoactive compounds of the mdma class |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9209599D0 (en) | 1992-05-02 | 1992-06-17 | Fisons Corp | Novel therapy for the treatment of parkinsons disease |
| CA2475026A1 (en) | 1999-12-01 | 2001-06-07 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| US6417184B1 (en) * | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| US8354438B2 (en) * | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| CA2459146A1 (en) | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| AU2002340971B2 (en) | 2001-10-08 | 2007-04-26 | Ucb | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
| AU2003239752A1 (en) * | 2002-06-27 | 2004-01-19 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| US7390505B2 (en) | 2003-01-31 | 2008-06-24 | Elan Pharma International, Ltd. | Nanoparticulate topiramate formulations |
| MX2007013882A (es) | 2005-05-06 | 2008-01-28 | Portela & Ca Sa | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| AU2008279636A1 (en) | 2007-07-25 | 2009-01-29 | The Regents Of The University Of Colorado | Central administration of stable formulations of therapeutic agents for CNS conditions |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| US20110065674A1 (en) | 2008-05-14 | 2011-03-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2331088A4 (en) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES |
| EA202092673A3 (ru) | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| WO2011143721A1 (en) | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
-
2007
- 2007-03-30 WO PCT/AU2007/000421 patent/WO2008095221A1/en not_active Ceased
- 2007-03-30 AU AU2007346591A patent/AU2007346591A1/en not_active Abandoned
-
2008
- 2008-02-07 EP EP08700447.9A patent/EP2129369B1/en not_active Not-in-force
- 2008-02-07 WO PCT/AU2008/000154 patent/WO2008095253A1/en not_active Ceased
- 2008-02-07 US US12/526,191 patent/US8957099B2/en not_active Expired - Fee Related
- 2008-02-07 JP JP2009548546A patent/JP5586962B2/ja not_active Expired - Fee Related
- 2008-02-07 ES ES08700447T patent/ES2426764T3/es active Active
- 2008-02-07 EP EP12174063A patent/EP2505197A1/en not_active Withdrawn
-
2014
- 2014-07-23 JP JP2014149462A patent/JP2014196370A/ja active Pending
- 2014-12-30 US US14/586,081 patent/US9649297B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100087422A1 (en) | 2010-04-08 |
| WO2008095253A1 (en) | 2008-08-14 |
| ES2426764T3 (es) | 2013-10-25 |
| JP2010518027A (ja) | 2010-05-27 |
| US20150313877A1 (en) | 2015-11-05 |
| EP2129369A1 (en) | 2009-12-09 |
| US8957099B2 (en) | 2015-02-17 |
| EP2129369A4 (en) | 2010-04-21 |
| JP5586962B2 (ja) | 2014-09-10 |
| EP2129369B1 (en) | 2013-06-05 |
| JP2014196370A (ja) | 2014-10-16 |
| US9649297B2 (en) | 2017-05-16 |
| WO2008095221A1 (en) | 2008-08-14 |
| EP2505197A1 (en) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007346591A1 (en) | Treatment of ADHD | |
| Lee et al. | Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up | |
| Friedman et al. | Guanfacine treatment of cognitive impairment in schizophrenia | |
| Park et al. | Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients | |
| Bloch et al. | N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial | |
| Liotti et al. | Evidence for specificity of ERP abnormalities during response inhibition in ADHD children: A comparison with reading disorder children without ADHD | |
| Prevey et al. | Complex partial and secondarily generalized seizure patients: cognitive functioning prior to treatment with antiepileptic medication | |
| McNeely et al. | Neurophysiological evidence for disturbances of conflict processing in patients with schizophrenia. | |
| Maegawa et al. | Substrate reduction therapy in juvenile GM2 gangliosidosis | |
| Dickstein et al. | Cognitive remediation: potential novel brain-based treatment for bipolar disorder in children and adolescents | |
| Lancman et al. | The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy | |
| Lewis et al. | Cortical inhibitory and excitatory correlates of depression severity in children and adolescents | |
| Loe et al. | Oculomotor performance identifies underlying cognitive deficits in attention-deficit/hyperactivity disorder | |
| Hong et al. | Effects of risperidone on information processing and attention in first-episode schizophrenia | |
| Dickerson et al. | Neuropsychological deficits in chronic schizophrenics: Relationship with symptoms and behavior | |
| PLATT et al. | Effects of lithium carbonate and haloperidol on cognition in aggressive hospitalized school-age children | |
| Rothenberger | Brain and behavior in child psychiatry | |
| Chase et al. | A new chemotherapeutic investigation: Piracetam effects on dyslexia | |
| Äikiä et al. | Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy | |
| Oscar-Berman et al. | Nonmatching-(oddity) and delayed nonmatching-to-sample performance in aging, alcoholic, and alcoholic Korsakoff individuals | |
| Winograd-Gurvich et al. | Inhibitory control and spatial working memory: A saccadic eye movement study of negative symptoms in schizophrenia | |
| Pearson et al. | Psychopharmacology: Issues in prescribing psychiatric medication to children and adolescents | |
| AU2008213908B2 (en) | Treatment of ADHD | |
| Goldenberg | HEMISPHERIC INTEGRATION THERAPY IN THE TREATMENT OF ADHD | |
| Rakusa | Epilepsy and Impact on Cognition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |